CA2830362A1 - Methods of diagnosing and treating intestinal granulomas and low bone density in inflammatory bowel disease - Google Patents
Methods of diagnosing and treating intestinal granulomas and low bone density in inflammatory bowel disease Download PDFInfo
- Publication number
- CA2830362A1 CA2830362A1 CA2830362A CA2830362A CA2830362A1 CA 2830362 A1 CA2830362 A1 CA 2830362A1 CA 2830362 A CA2830362 A CA 2830362A CA 2830362 A CA2830362 A CA 2830362A CA 2830362 A1 CA2830362 A1 CA 2830362A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- risk
- genetic variant
- present
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 59
- 208000029725 Metabolic bone disease Diseases 0.000 title claims abstract description 51
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 37
- 206010018691 Granuloma Diseases 0.000 title claims abstract description 32
- 230000000968 intestinal effect Effects 0.000 title description 4
- 230000002068 genetic effect Effects 0.000 claims abstract description 71
- 230000000405 serological effect Effects 0.000 claims abstract description 38
- 239000003550 marker Substances 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 48
- 201000010099 disease Diseases 0.000 claims description 45
- 208000011231 Crohn disease Diseases 0.000 claims description 34
- 241001408449 Asca Species 0.000 claims description 24
- 208000001132 Osteoporosis Diseases 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims description 8
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims description 8
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims description 8
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 claims description 7
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 claims description 7
- 108050009312 plexin Proteins 0.000 claims description 7
- 102000002022 plexin Human genes 0.000 claims description 7
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims description 6
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 6
- 102100021597 Endoplasmic reticulum aminopeptidase 2 Human genes 0.000 claims description 6
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 6
- 101000634537 Homo sapiens Neuronal PAS domain-containing protein 2 Proteins 0.000 claims description 6
- 102100034256 Mucin-1 Human genes 0.000 claims description 6
- 102100029045 Neuronal PAS domain-containing protein 2 Human genes 0.000 claims description 6
- 206010049088 Osteopenia Diseases 0.000 claims description 6
- 108010080821 leucine-rich amelogenin peptide Proteins 0.000 claims description 6
- 108090000174 Interleukin-10 Proteins 0.000 claims description 4
- 102000003814 Interleukin-10 Human genes 0.000 claims description 4
- 230000000149 penetrating effect Effects 0.000 claims description 4
- 241000045500 Diseae Species 0.000 claims description 2
- 102100030461 Alpha-ketoglutarate-dependent dioxygenase FTO Human genes 0.000 claims 2
- 101001062620 Homo sapiens Alpha-ketoglutarate-dependent dioxygenase FTO Proteins 0.000 claims 2
- -1 TNIFSF15 Proteins 0.000 claims 1
- 108700028369 Alleles Proteins 0.000 description 39
- 239000000523 sample Substances 0.000 description 27
- 102000054766 genetic haplotypes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 206010024229 Leprosy Diseases 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 230000008506 pathogenesis Effects 0.000 description 7
- 230000003321 amplification Effects 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 230000037182 bone density Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000033687 granuloma formation Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 102000012064 NLR Proteins Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000012252 genetic analysis Methods 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 102100020997 Fractalkine Human genes 0.000 description 2
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108700028353 OmpC Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000002060 circadian Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
- 102000050697 Nod2 Signaling Adaptor Human genes 0.000 description 1
- 108700002045 Nod2 Signaling Adaptor Proteins 0.000 description 1
- 101150083031 Nod2 gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091006764 Organic cation transporters Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108091006736 SLC22A5 Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102100036924 Solute carrier family 22 member 5 Human genes 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000001234 inflammatory bowel disease 5 Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467881P | 2011-03-25 | 2011-03-25 | |
| US201161467779P | 2011-03-25 | 2011-03-25 | |
| US61/467,779 | 2011-03-25 | ||
| US61/467,881 | 2011-03-25 | ||
| PCT/US2012/030614 WO2012135144A2 (en) | 2011-03-25 | 2012-03-26 | Methods of diagnosing and treating intestinal granulomas and low bone density in inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2830362A1 true CA2830362A1 (en) | 2012-10-04 |
Family
ID=46932277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2830362A Abandoned CA2830362A1 (en) | 2011-03-25 | 2012-03-26 | Methods of diagnosing and treating intestinal granulomas and low bone density in inflammatory bowel disease |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140018447A1 (enExample) |
| EP (2) | EP3330711A1 (enExample) |
| JP (2) | JP2014515599A (enExample) |
| CA (1) | CA2830362A1 (enExample) |
| WO (1) | WO2012135144A2 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10633449B2 (en) | 2013-03-27 | 2020-04-28 | Cedars-Sinai Medical Center | Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway |
| US11186872B2 (en) | 2016-03-17 | 2021-11-30 | Cedars-Sinai Medical Center | Methods of diagnosing inflammatory bowel disease through RNASET2 |
| US11236393B2 (en) | 2008-11-26 | 2022-02-01 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease |
| US11312768B2 (en) | 2013-07-19 | 2022-04-26 | Cedars-Sinai Medical Center | Signature of TL1A (TNFSF15) signaling pathway |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12402960B2 (en) | 2010-10-11 | 2025-09-02 | Ecole Polytechnique Federale De Lausanne (Epfl) | Mechanical manipulator for surgical instruments |
| EP2627278B1 (en) | 2010-10-11 | 2015-03-25 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Mechanical manipulator for surgical instruments |
| WO2013014621A2 (en) | 2011-07-27 | 2013-01-31 | Ecole Polytechnique Federale De Lausanne (Epfl) | Mechanical teleoperated device for remote manipulation |
| CA2830362A1 (en) * | 2011-03-25 | 2012-10-04 | Dermot P. Mcgovern | Methods of diagnosing and treating intestinal granulomas and low bone density in inflammatory bowel disease |
| US10265129B2 (en) | 2014-02-03 | 2019-04-23 | Distalmotion Sa | Mechanical teleoperated device comprising an interchangeable distal instrument |
| EP3185808B1 (en) | 2014-08-27 | 2022-02-23 | DistalMotion SA | Surgical system for microsurgical techniques |
| EP3653145B1 (en) | 2014-12-19 | 2024-01-24 | DistalMotion SA | Reusable surgical instrument for minimally invasive procedures |
| WO2016097861A1 (en) | 2014-12-19 | 2016-06-23 | Distalmotion Sa | Sterile interface for articulated surgical instruments |
| DK3232951T3 (da) | 2014-12-19 | 2024-01-15 | Distalmotion Sa | Kirurgisk instrument med leddelt ende-effektor |
| WO2016097871A1 (en) | 2014-12-19 | 2016-06-23 | Distalmotion Sa | Docking system for mechanical telemanipulator |
| WO2016097873A2 (en) | 2014-12-19 | 2016-06-23 | Distalmotion Sa | Articulated handle for mechanical telemanipulator |
| EP3280337B1 (en) | 2015-04-09 | 2019-11-13 | DistalMotion SA | Articulated hand-held instrument |
| EP4484082A3 (en) | 2015-04-09 | 2025-03-12 | Distalmotion SA | Mechanical teleoperated device for remote manipulation |
| EP3340897B1 (en) | 2015-08-28 | 2024-10-09 | DistalMotion SA | Surgical instrument with increased actuation force |
| US11058503B2 (en) | 2017-05-11 | 2021-07-13 | Distalmotion Sa | Translational instrument interface for surgical robot and surgical robot systems comprising the same |
| US10477105B2 (en) * | 2017-06-08 | 2019-11-12 | Futurewei Technologies, Inc. | Method and system for transmitting virtual reality (VR) content |
| US12376927B2 (en) | 2018-02-07 | 2025-08-05 | Distalmotion Sa | Surgical robot systems comprising robotic telemanipulators and integrated laparoscopy |
| EP3749243A1 (en) | 2018-02-07 | 2020-12-16 | Distalmotion SA | Surgical robot systems comprising robotic telemanipulators and integrated laparoscopy |
| WO2023037273A1 (en) | 2021-09-13 | 2023-03-16 | Distalmotion Sa | Instruments for surgical robotic system and interfaces for the same |
| US11844585B1 (en) | 2023-02-10 | 2023-12-19 | Distalmotion Sa | Surgical robotics systems and devices having a sterile restart, and methods thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916748A (en) * | 1996-04-12 | 1999-06-29 | Cedars-Sinai Medical Center | Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis |
| USH2191H1 (en) * | 2000-10-24 | 2007-06-05 | Snp Consortium | Identification and mapping of single nucleotide polymorphisms in the human genome |
| US20040053263A1 (en) * | 2002-08-30 | 2004-03-18 | Abreu Maria T. | Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease |
| EP1613960B1 (en) * | 2003-04-11 | 2009-06-03 | Cedars-Sinai Medical Center | Methods of assessing crohn's disease patient phenotype by i2, ompc and asca serologic response |
| US7662569B2 (en) * | 2003-04-11 | 2010-02-16 | Cedars-Sinai Medical Center | Methods of assessing Crohn's disease patient phenotype by I2 serologic response |
| US20100015156A1 (en) * | 2007-03-06 | 2010-01-21 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease in children |
| US20100129838A1 (en) * | 2008-11-11 | 2010-05-27 | Prometheus Laboratories Inc. | Methods for prediction of inflammatory bowel disease (ibd) using serologic markers |
| CA2830362A1 (en) * | 2011-03-25 | 2012-10-04 | Dermot P. Mcgovern | Methods of diagnosing and treating intestinal granulomas and low bone density in inflammatory bowel disease |
-
2012
- 2012-03-26 CA CA2830362A patent/CA2830362A1/en not_active Abandoned
- 2012-03-26 EP EP17208382.6A patent/EP3330711A1/en not_active Withdrawn
- 2012-03-26 US US14/007,391 patent/US20140018447A1/en not_active Abandoned
- 2012-03-26 WO PCT/US2012/030614 patent/WO2012135144A2/en not_active Ceased
- 2012-03-26 EP EP12765854.0A patent/EP2689036B1/en not_active Not-in-force
- 2012-03-26 JP JP2014501305A patent/JP2014515599A/ja active Pending
-
2016
- 2016-08-26 JP JP2016165692A patent/JP2016198116A/ja not_active Ceased
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11236393B2 (en) | 2008-11-26 | 2022-02-01 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease |
| US12084722B2 (en) | 2008-11-26 | 2024-09-10 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease |
| US10633449B2 (en) | 2013-03-27 | 2020-04-28 | Cedars-Sinai Medical Center | Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway |
| US11312768B2 (en) | 2013-07-19 | 2022-04-26 | Cedars-Sinai Medical Center | Signature of TL1A (TNFSF15) signaling pathway |
| US12269873B2 (en) | 2013-07-19 | 2025-04-08 | Cedars-Sinai Medical Center | Signature of TL1A (TNFSF15) signaling pathway |
| US11186872B2 (en) | 2016-03-17 | 2021-11-30 | Cedars-Sinai Medical Center | Methods of diagnosing inflammatory bowel disease through RNASET2 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012135144A3 (en) | 2013-12-27 |
| WO2012135144A2 (en) | 2012-10-04 |
| EP3330711A1 (en) | 2018-06-06 |
| JP2016198116A (ja) | 2016-12-01 |
| US20140018447A1 (en) | 2014-01-16 |
| EP2689036A4 (en) | 2015-04-15 |
| EP2689036B1 (en) | 2017-12-20 |
| JP2014515599A (ja) | 2014-07-03 |
| EP2689036A2 (en) | 2014-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2689036B1 (en) | Methods of diagnosing and treating intestinal granulomas and low bone density in inflammatory bowel disease | |
| US20110177969A1 (en) | The role of il17rd and the il23-1l17 pathway in crohn's disease | |
| US20100184050A1 (en) | Diagnosis and treatment of inflammatory bowel disease in the puerto rican population | |
| US20100055700A1 (en) | Role of il-12, il-23 and il-17 receptors in inflammatory bowel disease | |
| US20100144903A1 (en) | Methods of diagnosis and treatment of crohn's disease | |
| US8153443B2 (en) | Characterization of the CBir1 antigenic response for diagnosis and treatment of Crohn's disease | |
| WO2009052512A2 (en) | Methods of using genetic variants to diagnose and predict inflammatory bowel disease | |
| US20100021917A1 (en) | Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease | |
| US9902996B2 (en) | Methods of predicting the need for surgery in crohn's disease | |
| US20150086567A1 (en) | Role of ifng methylation in inflammatory bowel disease | |
| US20180208988A1 (en) | Methods of diagnosis and treatment of inflammatory bowel disease | |
| US20130012602A1 (en) | Methods of using znf365 genetic variants to diagnose crohn's disease | |
| EP2689034B1 (en) | Role of ifng methylation in inflammatory bowel disease | |
| US9305137B1 (en) | Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach | |
| WO2011088306A1 (en) | Methods of using genetic variants to diagnose crohn's disease | |
| US20120041082A1 (en) | Methods of using smad3 and jak2 genetic variants to diagnose and predict inflammatory bowel disease | |
| EP2689246B1 (en) | Methods of diagnosing ulcerative colitis and crohn's disease | |
| US20120190698A1 (en) | Methods of predicting thiopurine response | |
| WO2008112990A2 (en) | Methods of diagnosis and treatment of crohn's disease | |
| WO2009055596A2 (en) | Methods of using genetic variants to diagnose and predict metabolic syndrome and associated traits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170301 |
|
| FZDE | Dead |
Effective date: 20190618 |